Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Deepu Madduri(Johnson & Johnson (United States)), Jesús G. Berdeja(Tennessee Oncology), Enrique Zudaire(Centro de Investigación del Cáncer), Sundar Jagannath(Mount Sinai Hospital), Syed Rizvi(Merck (Japan)), Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), Xiao-Hu Fan, Jordan M. Schecter(Centro de Investigación del Cáncer), Tzu‐Min Yeh(Centro de Investigación del Cáncer), Indrajeet Singh(Janssen (United States)), Jeffrey R. Infante(Cancer Research Center), Alicia J. Allred(Queen's University Belfast), Sen Hong Zhuang(Janssen (United States)), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 120
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k